Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership. 2022

Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
Laboratory of Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.

Transforming growth factor-beta1 (TGF-β1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-β1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-β1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-β1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-β1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072737 Myeloid-Derived Suppressor Cells A heterogeneous, immature population of myeloid cells that can suppress the activity of T-CELLS and NATURAL KILLER CELLS in the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNE RESPONSE. They play important roles in ONCOGENESIS; INFLAMMATION; and INFECTION. MDSC,Myeloid Derived Suppressor Cell,MDSCs,Cell, Myeloid-Derived Suppressor,Cells, Myeloid-Derived Suppressor,Myeloid Derived Suppressor Cells,Myeloid-Derived Suppressor Cell,Suppressor Cell, Myeloid-Derived,Suppressor Cells, Myeloid-Derived
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D019139 Tumor Escape The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 ANTIGENS and B7-1 ANTIGEN. Immune Escape, Tumor,Immune Evasion, Tumor,Tumor Immune Evasion,Evasion, Tumor Immune,Evasions, Tumor Immune,Immune Evasions, Tumor,Tumor Immune Escape,Tumor Immune Evasions

Related Publications

Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
May 2024, International journal of radiation oncology, biology, physics,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
January 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
March 2015, Current opinion in nephrology and hypertension,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
January 1991, Cancer immunology, immunotherapy : CII,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
March 1996, The Journal of biological chemistry,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
April 2009, Cell biochemistry and function,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
August 2005, Pancreas,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
October 1998, The European respiratory journal,
Slavko Mojsilovic, and Sonja S Mojsilovic, and Suncica Bjelica, and Juan F Santibanez
August 2006, Medical science monitor : international medical journal of experimental and clinical research,
Copied contents to your clipboard!